MRD has great importance in the management of MM. MRD status is a known prognostic factor, which has the potential for clinical trial improvement, treatment guidance and treatment-free remission1-3.

With the growth of this field come many questions, including whether drug administration should be continued in a MM patient who is MRD negative, or whether to change the treatment given if a patient is MRD positive4,5

  1. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013 Jul 10; 31(20): 2540-2547.
  2. Anderson KC, Auclair D, Kelloff GJ, et al. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clin Cancer Res. 2017 Aug 1; 23(15): 3980-3993.
  3. VJHemOnc (2018). MRD measurement as a strategy for treatment-free survival. Available at: https://www.vjhemonc.com/video/_yh3t_zgz5i-mrd-measurement-as-a-strategy-for-treatment-free-survival (Accessed: 03 July 2018).
  4. Landgren O, Owen RG. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient. Cytometry B Clin Cytom. 2016 Jan; 90(1): 14-20.
  5. VJHemOnc (2018). The importance of MRD status in MM. Available at: https://www.vjhemonc.com/video/fcqj3vgls2e-the-importance-of-mrd-status-in-mm (Accessed: 03 July 2018).
View overview page

MRD and Multiple Myeloma

MRD content on VJHemOnc.com is sponsored by AbbVie Ltd and Adaptive Biotechnologies. The companies have no influence over the production of the content

MRD and Multiple Myeloma

MRD has great importance in the management of MM. MRD status is a known prognostic factor, which has the potential for clinical trial improvement, treatment guidance and treatment-free remission1-3.

With the growth of this field come many questions, including whether drug administration should be continued in a MM patient who is MRD negative, or whether to change the treatment given if a patient is MRD positive4,5

  1. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013 Jul 10; 31(20): 2540-2547.
  2. Anderson KC, Auclair D, Kelloff GJ, et al. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clin Cancer Res. 2017 Aug 1; 23(15): 3980-3993.
  3. VJHemOnc (2018). MRD measurement as a strategy for treatment-free survival. Available at: https://www.vjhemonc.com/video/_yh3t_zgz5i-mrd-measurement-as-a-strategy-for-treatment-free-survival (Accessed: 03 July 2018).
  4. Landgren O, Owen RG. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient. Cytometry B Clin Cytom. 2016 Jan; 90(1): 14-20.
  5. VJHemOnc (2018). The importance of MRD status in MM. Available at: https://www.vjhemonc.com/video/fcqj3vgls2e-the-importance-of-mrd-status-in-mm (Accessed: 03 July 2018).
View overview page
MRD content on VJHemOnc.com is sponsored by AbbVie Ltd and Adaptive Biotechnologies. The companies have no influence over the production of the content